Desvenlafaxine in Opioid-Dependent Patients

NATURE AND OBJECTIVES OF THE PROJECT
Patients who suffer from addiction to opioids often experience depression. Furthermore, data concerning the use of effective medication to treat depression in patients addicted to opioids is insufficient. Desvenlafaxine is an antidepressant that has been approved in Canada to treat depression within the general population. We hereby intend to conduct a research project to evaluate whether Desvenlafaxine is a tolerable and acceptable treatment for opioid-dependant patients undergoing methadone treatment at the CHUM addiction clinic and other methadone clinics in the Greater Montreal region. Presently, we are posting project researchs information at the CHUM addiction clinic, the Centre de recherche
et d’aide pour narcomanes (CRAN) and the CRD Le Virage. We will also assess the effects of this medication on depressive symptoms.
NUMBER OF PARTICIPANTS AND DURATION OF PARTICIPATION
The study will include 20 patients undergoing methadone treatment and suffering from opioid addiction and depression. Your participation will last 8 weeks.

Faculty Supervisor:

Didier Jutras-Aswad

Student:

Cynthia El Hage

Partner:

Pfizer Canada Inc.

Discipline:

Pharmacy / Pharmacology

Sector:

Life sciences

University:

Program: